Imiquimod (IMQ) is often used as a topical challenge agent to provoke local skin inflammation. The objective of this study was to develop and refine a rapid, temporary, and reversible human skin inflammation model with IMQ for application in clinical drug development. A randomized, vehicle-controlled, open-label, dose-ranging study was conducted in 16 healthy male subjects. IMQ (5 mg) was applied once daily for 72 hours under occlusion to intact skin (n = 8) or tape stripped (TS) skin (n = 8). Although IMQ alone induced limited effects, TS+IMQ treatment showed larger responses in several domains, including erythema and perfusion (P < 0.0001), mRNA expression of inflammatory markers (P < 0.01), and inflammatory cell influx compared with vehicle. In conclusion, a rapid, human IMQ skin inflammation challenge model was successfully developed with a clear benefit of TS prior to IMQ application. Future interaction studies will enable proof-of-pharmacology of novel compounds targeting the innate immune system.

Additional Metadata
Persistent URL dx.doi.org/10.1111/cts.12563, hdl.handle.net/1765/109542
Journal Clinical and Translational Science
Citation
Niemeyer - van der Kolk, T, Assil, S. (Salma), Rijneveld, R. (Rianne), Klaassen, E.S, Feiss, G. (Gary), Florencia, E, … van Doorn, M.B.A. (2018). Comprehensive, Multimodal Characterization of an Imiquimod-Induced Human Skin Inflammation Model for Drug Development. Clinical and Translational Science. doi:10.1111/cts.12563